Waterdrop reported strong second quarter 2026 revenue growth, approved a US$0.03 ADS dividend, and launched a US$50 million ...
AstraZeneca reported Phase III results showing tozorakimab reduced COPD exacerbations across patient groups as FDA reviews ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results